Skip NavigationMarketsBusinessInvestingTechPolitics & PolicyVideoWatchlistInvesting Club
PRO
LivestreamMenuThe S & P 500 snapped a three-week winning streak as a runup in Treasury yields weighed on the market. Still, some individual stocks surged on the week, entering overbought territory. The broad market index posted a 0.4% advance on Friday, but still notched a 1.4% loss on the week. A runup in bond yields, particularly on longer-dated Treasurys, sparked a sell-off on Thursday, ultimately denting the major averages’ weekly performance. Using LSEG data, CNBC Pro screened the S & P 500 for stocks with a 14-day relative strength index, or RSI, above 70. An RSI reading above 70 is generally considered a sign that a stock is overbought, meaning it could be more vulnerable to a pullback. Here are the most overbought stocks this week: Moderna and Merck were among the most notable names on the list. Shares of both companies soared this week after they announced positive initial results from an experimental personalized cancer vaccine in its first-ever late-stage trial. The vaccine, in combination with Keytruda , met key goals in patients with higher-risk or advanced melanoma whose detectable cancer had been completely removed through surgery. Moderna was the biggest weekly gainer on the CNBC’s Pro screen with a surge of 129%. It has an RSI reading of 70 and a hold consensus rating, while Merck gained 12% for the week. The stock has an RSI of 77 and carries a buy consensus from analysts. Estée Lauder landed in overbought territory after a sharp earnings-driven rally. Shares were up more than 18% on the week. On Wednesday, the cosmetics company surpassed the Street’s expectations on the top and bottom lines in the fourth quarter. Estee Lauder also lifted its adjusted operating margin for the fiscal year 2027 to a range of 12.7% to 13.5%, up from its earlier call for 12.5% to 13%. The company also said it expects adjusted earnings of between $3.10 to $3.35 per share in fiscal 2027, encompassing the FactSet consensus call of $3.19 per share. “For fiscal 2027, we are affirming our confidence to accelerate organic sales growth. In addition, we are raising our outlook for an even stronger adjusted operating margin, as we double down on our strengths to further diversify growth,” Stéphane de La Faverie, president and CEO said. Other names on the overbought list included Agilent Technologies , which had the highest RSI in the screen at 79, and Thermo Fisher Scientific , with an RSI of 71. Both carry buy consensus ratings from Wall Street analysts.Read More
About The Author
